Because patients with a higher copy number of SMN2 tend to develop SMA with later onset and/or show relatively milder symptoms [9,14], increasing the level of full-length functional SMN protein from SMN2 is expected to alleviate symptoms in patients with SMA [15]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.